Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0231 | 0.5717 | 0.4698 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0101 | 0.1923 | 0.31 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0378 | 1 | 0.5 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0248 | 0.6203 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0101 | 0.1923 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0378 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0257 | 0.6471 | 0.5631 |
Brugia malayi | glutathione reductase | 0.0101 | 0.1923 | 0.31 |
Echinococcus multilocularis | geminin | 0.0202 | 0.4858 | 1 |
Echinococcus granulosus | geminin | 0.0202 | 0.4858 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0102 | 0.1941 | 0.3995 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0257 | 0.6471 | 1 |
Leishmania major | trypanothione reductase | 0.0101 | 0.1923 | 0.5 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0231 | 0.5717 | 0.4698 |
Plasmodium vivax | glutathione reductase, putative | 0.0101 | 0.1923 | 0.1923 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0049 | 0.0395 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0378 | 1 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0231 | 0.5717 | 0.4698 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0049 | 0.0395 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0101 | 0.1923 | 0.31 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0049 | 0.0395 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0231 | 0.5717 | 0.4698 |
Toxoplasma gondii | thioredoxin reductase | 0.0101 | 0.1923 | 1 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0378 | 1 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0049 | 0.0395 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0101 | 0.1923 | 0.5 |
Onchocerca volvulus | 0.0282 | 0.7204 | 1 | |
Brugia malayi | Pre-SET motif family protein | 0.0248 | 0.6203 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0378 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0202 | 0.4858 | 0.5766 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0378 | 1 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.0282 | 0.7204 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0101 | 0.1923 | 0.1923 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0231 | 0.5717 | 0.4698 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0049 | 0.0395 | 0.5 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0257 | 0.6471 | 0.5631 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0257 | 0.6471 | 0.5631 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0378 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable reductase | 0.0231 | 0.5717 | 0.4698 |
Schistosoma mansoni | hypothetical protein | 0.0202 | 0.4858 | 0.5766 |
Loa Loa (eye worm) | glutathione reductase | 0.0101 | 0.1923 | 0.31 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0102 | 0.1941 | 0.3995 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.